Back to the main directory
EarningsReview / Equity
- Schouw & Co - Buy/DKK 665: BioMar continues its impressive performance by Nordea
- Zealand Pharma - Much potential but too much already baked in by Danske Bank Equity Research
- Alm. Brand - It’s a bumpy ride but 2025 case remains largely intact by Danske Bank Equity Research
- Embracer - Asmodee can motivate the entire value of the group by Danske Bank Equity Research
- M2i Formation - Q2 Revenue by MidCap Partners
- Centre Testing Intl Group (300012 CH) by HSBC
- 华测检测（300012 CH） by HSBC
- Canadian railway strike looming by BNP Paribas Exane
- Keyence Corp (6861 JP) by HSBC
- 重庆啤酒（600132 CH） by HSBC
- Kamux - Realigning expectations by Danske Bank Equity Research
- Li Ning (2331 HK) by HSBC
- Modulight - Cash burn moderates further, progress with PPT by Danske Bank Equity Research
- Tokmanni - The potential is not priced in by Danske Bank Equity Research
- Yuexiu Transport Infra (1052 HK) by HSBC
- Boozt (Hold, TP: SEK130.00) - Soft Q2 by DnB Markets
- Hexagon Composites (Buy, TP: NOK40.00) - Progressing ahead of expectations by DnB Markets
- Kojamo (Hold, TP: EUR10.00) - Q2 as warned, market as feared by DnB Markets
- B2Impact (Buy, TP: NOK10.70) - Set for investment uptick in H2 by DnB Markets
- SpareBank 1 Helgeland (Buy, TP: NOK136.00) - Low loan losses, but margin pressure by DnB Markets
- New Wave Group (Buy, TP: SEK130.00) - Craft teamwear North America by DnB Markets
- Tokmanni (Hold, TP: EUR12.00) - Shrinking customer base by DnB Markets
- Nibe Industrier (Hold, TP: SEK52.00) - More optimistic than peers by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- More Q2 results and other news by DnB Markets
- Zealand Pharma - Buy/DKK 1,025 (1,041): Well funded with an abundance of triggers ahead by Nordea
- Fortum - Good operational performance and strong balance sheet by Danske Bank Equity Research
- Ørsted - Just when I thought I was out, they pull me back in… by Danske Bank Equity Research
- M2i Formation - CA T2 2024 by MidCap Partners
- MINING MONITOR, STRATEGY, WEEKLY RECAP by BNP Paribas Exane
- Samsung Life Insurance (032830 KS) by HSBC
- Dentsu Group - Positive momentum by Edison Investment Research
- Most Read Research - Week 9-15 August 2024 by BNP Paribas Exane
- Chongqing Brewery (600132 CH) by HSBC
- Brazilian Financials by HSBC
- JD Health (6618 HK) by HSBC
- RugVista Group - Holding out for a hero by Danske Bank Equity Research
- Focus on retaining market leadership by BNP Paribas Exane
- Boozt - Cards stacked against it by Danske Bank Equity Research
- Hong Kong & China Gas (3 HK) by HSBC
- AKVA group (Hold, TP: NOK72.00) - Q2 beat, but order intake miss by DnB Markets
- Olav Thon (Buy, TP: NOK265.00) - Indication of increased investments by DnB Markets
- Salmones Camanchaca (Buy, TP: NOK27.00) - Soft underlying Q2 results by DnB Markets
- FLSmidth (Buy, TP: DKK420.00) - Mixed Q2 by DnB Markets
- Storskogen (Buy, TP: SEK11.00) - Foundation for 2025 established by DnB Markets
- Ambea (Buy, TP: SEK110.00) - Continued strong execution by DnB Markets
- GARO (Hold, TP: SEK26.00) - Recharging…please HOLD by DnB Markets
- Golar LNG Minor model adjustments by DnB Markets
- Weekly news, topics & discussion by DnB Markets
- Valuation and market update by DnB Markets